|
|
|
|
|
BMJ 1975, 4 500-502
|
|
|
|
The Fate of LDL
|
|
|
|
FH3: mutations in PCSK9 Proprotein
|
|
|
|
Familial Hypercholesterolaemia
|
|
|
|
LDL-C Distribution and CAD Incidence
|
|
|
|
LDL and Atherogenesis
|
|
|
|
Macrophages and Foam Cells
|
|
|
|
From Association to Cause
|
|
|
|
Problems with Early Trials
|
|
|
|
Effects of Statins
|
|
|
|
Statins:The Evidence Base.
|
|
|
|
CHD Risk Despite Statin Therapy
|
|
|
|
Early Primary and Secondary CVD Prevention Trials
|
|
|
|
PROVE-IT Trial
|
|
|
|
Intensive Lipid Lowering with Atorvastatin
|
|
|
|
Treat to New Targets: Lipid Effects
|
|
|
|
Primary Efficacy Outcome Measure: First Major
|
|
|
|
Statin Therapy in Secondary Prevention
|
|
|
|
Meta-Analysis Cardiovascular Outcomes I
|
|
|
|
Implications of Recent Trials Adult Treatment Panel III Guidelines
|
|
|
|
Statins and Stroke Reduction
|
|
|
|
Heart Protection Study Stroke Outcomes
|
|
|
|
SPARCL
|
|
|
|
High-Dose Atorvastatin after Stroke or Transient Ischaemic Attack
|
|
presentation (PPTX 5.5MB)
Share this page with your colleagues and friends: